My Companies
Notification
Account
Log Out
Login
JHS Svendgaard board approved reallocating preferential issue proceeds, raising capex to ₹11.75cr and reducing group infusion to ₹10.75cr, with timelines extended to March 2027 for greater business flexibility.
No events have occurred recently